The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
© Im et al; licensee BioMed Central Ltd. 2011
Received: 11 October 2010
Accepted: 25 May 2011
Published: 25 May 2011
Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years.Alanine racemase is a ubiquitous enzyme among bacteria and provides the essential cell wall precursor, D-alanine. Since it is absent in humans, this enzyme is an attractive target for the development of drugs against S. pneumoniae and other bacterial pathogens.
Here we report the crystal structure of alanine racemase from S. pneumoniae (AlrSP). Crystals diffracted to a resolution of 2.0 Å and belong to the space group P3121 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. Structural comparisons show that AlrSP shares both an overall fold and key active site residues with other bacterial alanine racemases. The active site cavity is similar to other Gram positive alanine racemases, featuring a restricted but conserved entryway.
We have solved the structure of AlrSP, an essential step towards the development of an accurate pharmacophore model of the enzyme, and an important contribution towards our on-going alanine racemase structure-based drug design project. We have identified three regions on the enzyme that could be targeted for inhibitor design, the active site, the dimer interface, and the active site entryway.
Despite great advances in the development of antibiotics, the most common cause of community-acquired pneumonia, Streptococcus pneumoniae, is still a globally important pathogen, especially in children and the elderly . This Gram-positive diplococcus is a leading cause not only of pneumonia, but also otitis media, bacteremia, and meningitis [2, 3]. In children, S. pneumoniae is estimated to cause more than one-third of the 2 million deaths due to acute respiratory infections [4, 5]. In the elderly, S. pneumoniae is the most common cause of fatal community-acquired pneumonia [6, 7]. In adults from industrialized countries, pneumococcal pneumonia accounts for at least 30% of all cases of community-acquired pneumonia admitted to hospital, with a fatality rate of 11% to 44% . In addition, co-infection of influenza patients with S. pneumoniae is known to exacerbate their clinical outcome : for example, 50% or more of the flu-associated mortality in the 1918-1919 Spanish Flu epidemic is believed to have resulted from pneumococcal superinfections [8, 9], and S. pneumoniae co-infection has been specifically correlated with the severity of the recent H1N1 pandemic influenza . The rate of antibiotic resistance in S. pneumoniae has escalated dramatically since penicillin-resistant strains were first detected in the 1970s [11–15]. About 40% of pneumococcal isolates displayed multidrug-resistant phenotypes (resistance to three or more antibiotics) across 38 countries in 2004 [16, 17]. To meet the challenge of increasing pneumococcal drug resistance it will be important to isolate new therapeutic compounds effective against S. pneumoniae through the identification of new target enzymes and the development of effective inhibitors to these targets.
The bacterial enzyme alanine racemase (Alr; E.C. 22.214.171.124) uses a covalently-bound pyridoxal 5"-phosphate (PLP) cofactor to catalyze the racemization of L-alanine and D-alanine, the latter being an essential component of the peptidoglycan layer in bacterial cell walls . Microbiological evidence has consistently shown this enzyme to be essential in bacteria . One apparent exception was found for the Mycobacterium smegmatis enzyme, which was able tolerate an insertion in its alanine racemase gene . But this exception was disproved with the report of an alanine racemase deletion mutant in M. smegmatis that did not grow without D-alanine supplementation . S. pneumoniae, unlike Escherichia coli or Pseudomonas aeruginosa, contains only one gene that codes for alanine racemase . The lack of alanine racemase function in eukaryotes  makes this enzyme an attractive target for antimicrobial drug development. Structural studies are crucial to structure-based drug design [23–25], and solving the crystal structure of alanine racemase from S. pneumoniae (AlrSP) is a crucial step towards designing inhibitors of this enzyme.
To date, crystal structures of alanine racemase enzymes from seven different bacteria have been published: Geobacillus stearothermophilus (AlrGS) [26–31], P. aeruginosa (DadXPA) , Streptomyces lavendulae (AlrSL) , Mycobacterium tuberculosis (AlrMT) , Bacillus anthracis (AlrBA) [35, 36], E. coli (AlrEC) , and Enterococcus faecalis (AlrEF) . Structures of this enzyme from a further six microorganisms have been deposited in the PDB: Bartonella henselae (PDB ID 3KW3), Oenococcus oeni (3HUR and 3CO8), Pseudomonas fluorescens (2ODO), Actinobacillus succinogenes (3C3K), Corynebacterium glutamicum (2DY3), and Staphylococcus aureus (3OO2). In all of these structures, Alr is a homodimeric enzyme formed by a head-to-tail association of two monomers. Each monomer is composed of an N-terminal α/β barrel and an extended β-strand domain at the C-terminus. The active site in each monomer is located in the centre of the α/β barrel and contains a pyridoxal phosphate (PLP) co-factor covalently connected to a lysine residue by an internal aldimine bond. The catalytic mechanism is thought to involve two bases, the same lysine, and a tyrosine contributed by the opposite monomer [30, 39, 40]. The entryway to the active site and the PLP binding site consists of residues from loops in the α/β barrel domain of one monomer and residues from the C-terminal domain of the other monomer, and is roughly conical, with its base oriented toward the outside of the enzyme . Structures of alanine racemase in complex with substrate analogs [27, 28, 30–32] and site-directed mutagenesis of the enzyme [31, 40, 41] have elucidated the reaction mechanism of the enzyme and verified the key roles of active site residues. Structures of alanine racemase complexed with alanine phosphonate and D-cycloserine (DCS) show that these inhibitors covalently bind to the PLP cofactor, which explains their ability to inhibit eukaryotic PLP-containing enzymes in a non-specific manner [27, 30, 37, 38].
Determining the structure of alanine racemase from a range of bacterial species is an important step towards its full characterization in anticipation of inhibitor design. Here, we report the structure of AlrSP, and compare it with other published alanine racemase structures. This crystal structure will contribute useful information towards our structure-based drug design research aimed at the identification and development of alanine racemase inhibitors.
Results and discussion
Structure determination and refinement
Data collection and structure refinement statistics
Unit cell parameters
a = 119.97 Å, b = 119.97 Å, c = 118.10 Å
α = 90°, β = 90°, γ = 120°
R-merge a (%)
23.03 - 2.00 (2.05 - 2.00)
Average B-factors (Å2)
Main chain atoms
Side chain atoms and waters
Bond lengths (Å)
Bond angles (deg)
No. of residues
No. of protein atoms
No. of PLP atoms
No. of benzoic acid atoms No. of water molecules
Residues in the Ramachandran plot
Most favored regions
Additionally allowed regions
Generously allowed regions
Overall structure of AlrSP
As an incidental finding, the AlrSP structure contained additional electron density within the A monomer, at the end of helix 1 in the N-terminal α/β barrel domain. This planar density resembled a carboxylated aromatic ring, therefore a benzoic acid molecule, which fitted and refined well, was modeled into this region, even though the compound was not added to purification or crystallization conditions (topology and parameters obtained from the Hetero-compound Information Centre-Uppsala, HIC-UP ). It is situated some distance away from both the active site entryway and the dimer interface.
Structural and biochemical comparison with closely related alanine racemases
Average r.m.s. differences (Å) between the Cα atoms of AlrSP and alanine racemase structures from other Gram-positive bacteria
Residues used in r.m.s. calculations
Kinetic parameters for the racemization of L- to D- and D- to L-alanine by alanine racemases from Gram-positive bacteria
The hinge angle of the A monomer of AlrSP, formed by the Cα atoms of residues 99, 38 and 270 in the N-terminal α/β barrel domain and the C-terminal β-strand domain, is 132.3°. This is well within the range of hinge angles found between corresponding residues in the other Gram-positive alanine racemase structures (127.6° for AlrBA, 129.4° for AlrGS, 131.6° for AlrEF, and 138.2° for AlrSL). The difference in the degree of tilt between the C-terminal domains for the five structures can be seen in Figure 3A. Hydrogen bonding between the C- and N-terminal tails of opposite monomers was proposed by LeMagueres et al. to account for the distinct domain orientations of AlrMT and DadXPA . Alanine racemase structures with extra residues at the N- and C-terminal tails, such as AlrGS and AlrBA, often form these hydrogen bonds, which are associated with smaller hinge angles (127.6° for AlrBA, 129.4° for AlrGS).
Although the hinge angle clearly varies from species to species for this enzyme, the active sites superpose very well. Further, there is no correlation between hinge angle and Vmax (data not shown). On the other hand, there is some correlation between alanine racemase activity and bacterial doubling time. For example, the enzyme from the slow growing M. tuberculosis is very slow compared to the same enzyme from the rapid growing M. smegmatis species. It has previously been noted that only the dimeric form of the enzyme is active  and that many of the alanine racemase enzymes with the strongest monomer-dimer association have been found to be the most active . A recent report has appeared looking at how enzyme activity in different alanine racemases relates to self-association affinity and this report confirms this assertion .
In the LLP moiety, the C4" atom of the PLP cofactor is linked to the NZ of Lys40 by a double bond in the trans- configuration, forming an internal aldimine as in other alanine racemase structures [29, 31–33]. The PLP cofactor is further stabilized by hydrogen bonds with the side chains of six residues (Tyr44, Arg136, His165, Ser203, Arg218 and Tyr352) and main chains of three residues (Ser203, Gly220, Asp221; Figure 4A). The hydrogen-bonded network also includes residues His199 and Tyr263", and was first described in AlrGS . All of these residues are strictly conserved across the Gram-positive structures, except for Asp221, which is replaced by an Ile in AlrBA and AlrGS, a Val in AlrEF, and a Leu in AlrSL [29, 33].
We observed electron density consistent with a carbamylated lysine at the NZ terminus of Lys129, as seen in most other alanine racemase structures. Lys129 refined well as a carbamylated residue in this structure and is hydrogen bonded to the neighboring arginine residue. Shaw et al.  noted that this lysine residue is highly conserved, and later studies suggested that it helps to position the nearby arginine residue (Arg136 in AlrSP) which interacts with the substrate's carboxylate group through hydrogen-bonding [28, 32]. Arg136 is further positioned in AlrSP by a hydrogen bond to Ser309. Sequences of alanine racemases that contain a lysine in position 129 almost always have an accompanying serine or cysteine residue in the equivalent of position 309 . Recently, the AlrBA structure was found to contain an aspargine residue bound to a chloride ion at the equivalent position of Lys129, which appears to play the same role as the carbamylated Lys of positioning the active site arginine . An alignment of alanine racemase sequences by Couñago et al. revealed that the presence of an aspargine residue can occur at the equivalent position of Lys129 in AlrSP and is likely to be indicative of an internal chloride within the active site in the place of a carbamylated lysine. Notably this change from Lys to Ser appears to always be accompanied by a threonine at the equivalent position of Ser309, even though the threonine does not directly interact with the chloride ion.
The environments on either side of the pyridine ring of PLP are quite different, as reported previously for AlrGS [29, 33]. The side of the PLP that faces the dimer interface is polar in character, with many hydrophilic amino acid residues (including carbamylated Lys129, Arg136, His165 and Arg218), several water molecules and the hydrogen-bond network. The nonpolar side of PLP, in contact with the α/β barrel, contains several hydrophobic residues (Val38, Leu83, Leu85 and Phe163), no charged residues and no water molecules.
As observed in several other alanine racemase structures [29, 32, 34, 36], we identified extra density in the active site of AlrSP adjacent to the PLP cofactor (Figure 4C). The position of this density corresponds to that of the acetate modeled in AlrGS. In other structures, this location has been reported to contain propionate, alanine phosphonate, and a putative substrate molecule in DadXPA [28–30, 38]. Water molecules in the same location are found in the AlrMT and AlrSL structures. After unsuccessfully attempting to model a variety of small molecules into the extra density, including acetate, we left this region of the model empty.
Active site entryway
The AlrSP active site entryway includes the conserved pair of acidic residues Asp170 and Glu171. The equivalent residues in E. coli, Asp164 and Glu165, have been posited to play a role in substrate orientation . Although the active sites of alanine racemases in general are moderate in size, it is difficult for inhibitors to access because of a constriction in the entryway corridor . The smallest constriction in the entryway corridor of AlrSP is between Tyr263' and Tyr352 of the inner layer (Figure 6A), which provide an opening width of only about 2.6Å for an active site inhibitor to pass through (the distance between the closest atoms of these two side chains with the van der Waals radius for each atom subtracted). As a result, the substrate entryway itself has been proposed as an alternative target for inhibitor development [32, 34]. Wang et al.  have proposed this idea previously for another enzyme, histone deacetylase-like protein.
Buried surface area (Å2)
% interface residues
Disruption of the dimer interface could be used to inhibit alanine racemase activity, and has been successfully used on drug targets in HIV and HCV [53–55], and on caspases . Inspection of the residues that participate in the dimer interface of AlrSP on a structure-based sequence alignment (Figure 2) makes it apparent that that many of these residues are highly conserved, and also participate in substrate guidance (such as middle and inner entryway residues Tyr282', Tyr352, Arg307', Ile350, Arg288', Asp170) or catalysis (e.g. Lys40, Tyr263').
Pentagonal water molecules in the active site
The hydrogen bond network we have identified could be facilitating substrate movement or proton transfer into the active site. Analysis of conserved water sites in AlrGS has been reported previously and the authors postulated that these sites could be involved in proton transfer or solvent shift into the active site . In the high resolution structure of the protein crambin, Teeter reported pentagonal rings of water molecules which were felt to have a role in stabilizing protein structure or in catalysis . Pentagonal ring waters have not yet been reported for other alanine racemases, but depending on which monomer is observed, the AlrBA and AlrGS structures have 3 to 4 of the 5 pentagonal waters present in AlrSP, the AlrSL structure has 2 of the 5 pentagonal waters, and the AlrEF structure does not have any pentagonal ring waters, although this could be due to limits in structural resolution.
Alanine racemase as a target for drug design
In this section we review some of the challenges encountered in developing inhibitors for alanine racemases as a family and we explain the contribution of the S. pneumoniae structure to this process. Finally we offer our assessment of the most useful approaches to alanine racemase inhibitor development.
Challenges involved in designing inhibitors for alanine racemase are easy to identify. To begin with, there have been few reports to date of alanine racemase inhibitors with any true specificity. Incorporating features of the active site in drug design has been challenging because the structure of the active site is thought to have limited accessibility. Further, several inhibitors have been found to cross react with human enzymes that contain PLP. Even so, our analysis of alanine racemase structures has allowed us to identify key features that could be incorporated into the inhibitor development process. Since these key features are also present in the S. pneumoniae enzyme structure, it confirms that these features are not artifacts or incidental findings but conserved features that can be targeted in the development of a class of inhibitors specific to bacterial alanine racemases. Therefore the structure of the S. pneumoniae enzyme is valuable to racemase drug design efforts.
In addition, one new feature relevant to the traditional drug design approach of blocking the active site that we report here for AlrSP is the pentagonal water network within the active site. Several of these waters are conserved in other alanine racemase species. That being the case, the conserved waters could be incorporated within an in silico pharmacophore as a polar site capable of receiving or donating a hydrogen bond depending on its protonation state. Unfortunately, to date testing of compounds identified from in silico screening has not resulted in the identification of strong inhibitors.
The earliest drug development work on alanine racemase was carried out in the absence of a crystal structure and resulted in the development of a cycloserine, a small, covalent inhibitor of alanine racemase and other PLP-containing enzymes  that lacks any specific interactions with elements in the active site. More recent in silico drug design work carried out using the structure of alanine racemase has defined a pharmacophore situated within the active site near the alanine racemase acetate binding site, a site reported consistently within alanine racemase structures . However, analysis of the narrow entryway to the active site PLP suggests that access to the proposed interior binding pockets of the enzyme is likely to be limited, especially for larger compounds [32, 34]. To be an effective drug target it is important the active site be accessible, therefore standard structure-aided inhibitor design approaches are limited for alanine racemase.
Since, as illustrated by the AlrSP structure, entryway to the interior binding pocket of alanine racemase is very tight, the drug design problem for alanine racemase resembles a "ship in a bottle" (SIAB) dilemma. Once inside the interior pocket, the compounds proposed to bind to the active site would fit well but these compounds may only make it to the interior with difficulty [32, 34, 36]. This view is of course an oversimplification, as the entryway is likely to 'breathe' and adjust, and there is a monomer-dimer equilibrium for alanine racemase that would affect the geometry and accessibility of internal active site cavities. However, the restricted access and size of the alanine racemase active site is one reason it has not been targeted by major pharmaceutical companies in the recent past (Bussiere, Dirk; personal communication).
If a drug design project involving an enzyme with a SIAB active site is to be successful, there are four obvious approaches to inhibitor development: high throughput screening (HTS), blocking the opening, interfering with active site assembly, or developing drugs that enter in one shape and adopt a new conformation after binding, thus trapping them in the active site.
HTS would bypass any of the complexities associated with active site access and would provide a set of compounds that inhibit the enzyme by any and all means, to be deconvoluted later. Given that the active site features we describe for the S. pneumoniae enzyme are highly conserved in the bacterial structures reported to date, the alanine racemase inhibitors identified by HTS would likely be broad-spectrum in their action. But a broad spectrum of activity should not be viewed in a negative light, as almost all major classes of antibiotics developed to date are broad spectrum. This includes beta-lactams like penicillin and cephalosporins, fluoroquinolones, tetracyclines, even macrolides. In fact the only specificity among anti-bacterial classes currently in use would be that some target preferentially Gram-positives, Gram-negatives, mycobacteria or anaerobes.
Blocking the opening would involve the design of compounds that interact with residues in the entryway and that extend toward the PLP moiety, but that might not reach the interior binding pocket. In our previous work on the alanine racemase from P. aeruginosa, M. tuberculosis and B. anthracis, we described a highly conserved and layered entryway to the active site that contains both hydrophobic and polar features. The hydrophobic regions are bound by three tyrosines and an alanine in the inner layer of entryway, while the polar areas include two arginines and one aspartate located in the middle layer. These highly conserved features are present in the S. pneumoniae structure and all alanine racemase structures reported to date. An entryway of this type has not been described in human PLP-containing enzymes. For example, human serine racemase, which like alanine racemase reacts with D-cycloserine, belongs to the Fold type II family of PLP-containing enzymes and would be not be expected to cross-react with any specific alanine racemase inhibitors . The alanine racemase topology is termed Fold type III and is unique among PLP-containing enzymes. It seems likely, therefore, that designing inhibitors that interact with conserved motifs found in the entryway could represent a potential source of specificity in the drug design process.
Interfering with active site assembly would, in the case of alanine racemase, require compounds that inhibit dimer formation, none of which have been reported for alanine racemase to date. However, dimer inhibitors have been reported in other systems such as HIV protease [53–55]. Finally, a compound that could enter the active site of alanine racemase then undergo a conformational switch rendering the enzyme inactive would make an effective inhibitor, but this type of inhibitor has not yet been reported for this class of enzyme.
Alanine racemase is a promising target for antibacterial drugs because it is both essential in bacteria and absent in humans. We report the high-resolution crystal structure of alanine racemase from S. pneumoniae. Overall, the structure shares the conserved active site and topology found across all alanine racemases. Known alanine racemase inhibitors such as D-cycloserine, alanine phosphonate, and other substrate analogues are not specific, acting on other PLP-containing enzymes such as transaminases, also found in humans [59, 62]. In order to be clinically relevant, new inhibitors of alanine racemase with more specificity need to be developed. This structure is an essential starting point for the design of more specific inhibitors of alanine racemase in S. pneumoniae. Our investigations have identified three potential areas in the AlrSP structure that could be targeted in a structure-based inhibitor design: the active site, the residues forming the dimer interface, and the active site entryway in particular, since designing a 'plug' to fit the funnel shape of this feature is intuitively attractive.
Protein expression, purification and crystallization
The expression, purification and crystallization of AlrSP have been described previously . Briefly, the gene encoding AlrSP was cloned into pET17 (Novagen) and the resulting vector transformed into E. coli BL21 (DE3) pLysS cells (Novagen). Overexpression of AlrSP was induced in a culture of these cells, which were then lysed to extract the protein. The recombinant AlrSP was purified using ammonium sulfate precipitation, anion-exchange chromatography, hydrophobic interaction chromatography, and finally, size-exclusion chromatography. Crystals of AlrSP were grown at 4°C in 1.2 M Na Citrate, 0.1 M MES, pH 7.2, and 10% glycerol (protein concentration 23 mg/ml, drop size 4 μl + 4 μl) using the sitting drop vapor diffusion method, then flash-frozen in liquid N2 for data collection. No additional cryoprotectant was required.
Data collection and processing
Diffraction data were collected to 2.0 Å resolution at 100 K using a Rigaku FR-E generator and an HTC detector at 45 kV and 45 mA with Cu Kα radiation at Rigaku MSC (The Woodlands, TX). The crystals belonged to the space group P3121 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. The data were processed and merged using the HKL package version 1.96.6 . Data collection and processing statistics are listed in Table 1.
Structure determination and refinement
The structure of AlrSP was solved by molecular replacement using CNS version 1.1 . AlrGS (PDB ID 1SFT)  without the PLP cofactor was used as a search model, and two monomers per asymmetric unit were assumed, as suggested by a Matthews coefficient  of 3.0 with a solvent content of 59.0%. Cross-rotation and translation searches were completed and the best solution was used as an initial model for model building. After rigid body refinement in CNS, ARP/wARP version 6.1  was used to trace the initial protein model and build side chains. Further refinement was carried out using simulated annealing and conjugation gradient minimization. When 97% of residues were built, the co-factor PLP and the carbamylated lysine were placed, and positional and B-factor refinements were continued resulting in an R and Rfree of 31.9 and 33.9%, respectively. Water molecules were added using the water-picking script in CNS, and further cycles of positional and Biso refinements brought the R and Rfree to 20.7 and 25.7%, respectively. Since previous alanine racemase structures have shown indications of subdomain movement, we tried TLS refinement . We used the TLS motion determination server [66, 67] to produce modified PDB files and TLS input files for the structure partitioned into either one, five or twenty TLS groups, then further refined these models in Refmac5 version 5.5.0109 . All models resulted in similar improvements in R and Rfree so we used the simplest option, which treated all protein atoms found in the asymmetric unit as a single rigid body (one TLS group). PLP and Lys40 were replaced with an LLP residue (PLP covalently bound to lysine), and TLS refinement was completed using Refmac5. The final model has an R and Rfree of 16.8 and 20.0%, respectively. Refinement statistics are listed in Table 1. Structure factors and final atomic coordinates for AlrSP have been deposited in the Protein Databank (PDB ID: 3S46). B-factor values and correlation coefficients were calculated using the programs Baverage and Overlapmap from the CCP4 suite .
Structural and sequence comparisons
The multiple structure-based sequence alignment and structural superpositions of AlrSP with closely related structures were performed using the protein structure comparison service (SSM) at the European Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/ssm) . The PDB IDs of the structures used were: 1SFT (AlrGS), 1VFH (AlrSL), 3HA1 (AlrBA), and 3E5P (AlrEF). Table 3 lists the residues from these structures used in the superpositions. Intermonomer interactions were analysed using the Protein Interfaces, Surfaces and Assemblies service (PISA) at the European Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) , and the Protein-Protein interface analysis server (PROTORP) Server (http://www.bioinformatics.sussex.ac.uk/protorp/ index.html) .
Representations of molecules were prepared using the programs PyMOL  and BKChem (http://bkchem.zirael.org/index.html). The sequence alignment was visualized using Jalview . The electrostatic potential of the AlrSP surface was calculated using the Adaptive Poisson-Boltzmann Solver (APBS)  through PyMOL. Default configurations were used for calculations. PQR files for use with APBS were generated using the PDB 2PQR Server (http://kryptonite.nbcr.net/pdb2pqr/)  and the Dundee PRODRG2 Server (http://davapc1.bioch.dundee.ac.uk/prodrg/) .
We wish to thank Eileen Murphy for her expert technical assistance, Pierre LeMagueres, Mitchell Miller, John J. Tanner and Sergey Lindeman for their expert crystallographic guidance, Michael J. Benedik and James M. Briggs for their helpful discussion and inspiration, and MSC Rigaku, especially Kris Tesh, for data collection assistance. Funding from the National Institutes of Health, the University of Otago, and the Robert A. Welch Foundation supported this work.
- Osler SW: Medicine in the Nineteenth Century. Aequanimitas: with other addresses to medical students, nurses and and practitioners of medicine. 1905, Philadelphia: P. Blakiston's Son & Co, 217-262.View ArticleGoogle Scholar
- Jedrzejas MJ: Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev. 2001, 65: 187-207. 10.1128/MMBR.65.2.187-207.2001.PubMedPubMed CentralView ArticleGoogle Scholar
- Hale KA, Isaacs D: Antibiotics in childhood pneumonia. Paediatr Respir Rev. 2006, 7: 145-151. 10.1016/j.prrv.2006.03.011.PubMedView ArticleGoogle Scholar
- World Health Organization Initiative for Vaccine Research: Acute Respiratory Infections (Update September 2009). [http://www.who.int/vaccine_research/diseases/ari/en/]
- O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009, 374: 893-902. 10.1016/S0140-6736(09)61204-6.PubMedView ArticleGoogle Scholar
- Bartlett JG, Froggatt JW: Antibiotic resistance. Arch Otolaryngol Head Neck Surg. 1995, 121: 392-396.PubMedView ArticleGoogle Scholar
- File TM: Community-acquired pneumonia. Lancet. 2003, 362: 1991-2001. 10.1016/S0140-6736(03)15021-0.PubMedView ArticleGoogle Scholar
- Brundage JF: Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006, 6: 303-312. 10.1016/S1473-3099(06)70466-2.PubMedView ArticleGoogle Scholar
- Klugman KP, Madhi SA: Pneumococcal vaccines and flu preparedness. Science. 2007, 316: 49-50.PubMedView ArticleGoogle Scholar
- Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V, Hui J, Tokarz R, Briese T, Baumeister E, Lipkin WI: Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS ONE. 2009, 4: e8540-10.1371/journal.pone.0008540.PubMedPubMed CentralView ArticleGoogle Scholar
- Krause KL, Stager C, Gentry LO: Prevalence of penicillin-resistant pneumococci in Houston, Texas. Am J Clin Pathol. 1982, 77: 210-213.PubMedGoogle Scholar
- Lynch JP, Zhanel GG: Streptococcus pneumoniae: does antimicrobial resistance matter?. Semin Respir Crit Care Med. 2009, 30: 210-238. 10.1055/s-0029-1202939.PubMedView ArticleGoogle Scholar
- Watson DA, Musher DM, Jacobson JW, Verhoef J: A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis. 1993, 17: 913-924. 10.1093/clinids/17.5.913.PubMedView ArticleGoogle Scholar
- File TM: Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect. 2006, 12 (Suppl 3): 31-41.PubMedView ArticleGoogle Scholar
- Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN: The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003, 52: 229-246. 10.1093/jac/dkg321.PubMedView ArticleGoogle Scholar
- Reinert RR: The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect. 2009, 15 (Suppl 3): 7-11.PubMedView ArticleGoogle Scholar
- Farrell DJ, Couturier C, Hryniewicz W: Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Int J Antimicrob Agents. 2008, 31: 245-249. 10.1016/j.ijantimicag.2007.10.022.PubMedView ArticleGoogle Scholar
- Lambert MP, Neuhaus FC: Factors affecting the level of alanine racemase in Escherichia coli. J Bacteriol. 1972, 109: 1156-1161.PubMedPubMed CentralGoogle Scholar
- Milligan DL, Tran SL, Strych U, Cook GM, Krause KL: The alanine racemase of Mycobacterium smegmatis is essential for growth in the absence of D-alanine. J Bacteriol. 2007, 189: 8381-8386. 10.1128/JB.01201-07.PubMedPubMed CentralView ArticleGoogle Scholar
- Chacon O, Feng Z, Harris NB, Caceres NE, Adams LG, Barletta RG: Mycobacterium smegmatis D-Alanine Racemase Mutants Are Not Dependent on D-Alanine for Growth. Antimicrob Agents Chemother. 2002, 46: 47-54. 10.1128/AAC.46.2.47-54.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Strych U, Davlieva M, Longtin J, Murphy E, Im H, Benedik M, Krause K: Purification and preliminary crystallization of alanine racemase from Streptococcus pneumoniae. BMC Microbiol. 2007, 7: 40-10.1186/1471-2180-7-40.PubMedPubMed CentralView ArticleGoogle Scholar
- Silverman RB: The potential use of mechanism-based enzyme inactivators in medicine. J Enzyme Inhib. 1988, 2: 73-90. 10.3109/14756368809040714.PubMedView ArticleGoogle Scholar
- Veerapandian B: Three dimensional structure-aided drug design. Burger's Medicinal Chemistry and Drug Discovery Volume 1. Edited by: Wolff ME. 1995, New York: John Wiley & Sons, Inc, 303-348. 5Google Scholar
- Marrone TJ, Briggs JM, McCammon JA: Structure-based drug design: computational advances. Annu Rev Pharmacol Toxicol. 1997, 37: 71-90. 10.1146/annurev.pharmtox.37.1.71.PubMedView ArticleGoogle Scholar
- Blundell TL: Structure-based drug design. Nature. 1996, 384: 23-26. 10.1038/384023a0.PubMedView ArticleGoogle Scholar
- Fenn TD, Holyoak T, Stamper GF, Ringe D: Effect of a Y265F mutant on the transamination-based cycloserine inactivation of alanine racemase. Biochemistry. 2005, 44: 5317-5327. 10.1021/bi047842l.PubMedView ArticleGoogle Scholar
- Fenn TD, Stamper GF, Morollo AA, Ringe D: A side reaction of alanine racemase: transamination of cycloserine. Biochemistry. 2003, 42: 5775-5783. 10.1021/bi027022d.PubMedView ArticleGoogle Scholar
- Morollo AA, Petsko GA, Ringe D: Structure of a Michaelis complex analogue: propionate binds in the substrate carboxylate site of alanine racemase. Biochemistry. 1999, 38: 3293-3301. 10.1021/bi9822729.PubMedView ArticleGoogle Scholar
- Shaw JP, Petsko GA, Ringe D: Determination of the structure of alanine racemase from Bacillus stearothermophilus at 1.9-Å resolution. Biochemistry. 1997, 36: 1329-1342. 10.1021/bi961856c.PubMedView ArticleGoogle Scholar
- Stamper GF, Morollo AA, Ringe D: Reaction of alanine racemase with 1-aminoethylphosphonic acid forms a stable external aldimine. Biochemistry. 1998, 37: 10438-10445. 10.1021/bi980692s.PubMedView ArticleGoogle Scholar
- Watanabe A, Yoshimura T, Mikami B, Hayashi H, Kagamiyama H, Esaki N: Reaction mechanism of alanine racemase from Bacillus stearothermophilus. J Biol Chem. 2002, 277: 19166-19172. 10.1074/jbc.M201615200.PubMedView ArticleGoogle Scholar
- LeMagueres P, Im H, Dvorak A, Strych U, Benedik M, Krause KL: Crystal structure at 1.45 Å resolution of alanine racemase from a pathogenic bacterium, Pseudomonas aeruginosa, contains both internal and external aldimine forms. Biochemistry. 2003, 42: 14752-14761. 10.1021/bi030165v.PubMedView ArticleGoogle Scholar
- Noda M, Matoba Y, Kumagai T, Sugiyama M: Structural evidence that alanine racemase from a D-cycloserine-producing microorganism exhibits resistance to its own product. J Biol Chem. 2004, 279: 46153-46161. 10.1074/jbc.M404605200.PubMedView ArticleGoogle Scholar
- LeMagueres P, Im H, Ebalunode J, Strych U, Benedik MJ, Briggs JM, Kohn H, Krause KL: The 1.9 Å crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site. Biochemistry. 2005, 44: 1471-1481. 10.1021/bi0486583.PubMedView ArticleGoogle Scholar
- Au K, Ren J, Walter TS, Harlos K, Nettleship JE, Owens RJ, Stuart DI, Esnouf RM: Structures of an alanine racemase from Bacillus anthracis (BA0252) in the presence and absence of (R)-1-aminoethylphosphonic acid (l-Ala-P). Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008, 64: 327-333. 10.1107/S1744309108007252.PubMedPubMed CentralView ArticleGoogle Scholar
- Couñago R, Davlieva M, Strych U, Hill R, Krause K: Biochemical and structural characterization of alanine racemase from Bacillus anthracis (Ames). BMC Struct Biol. 2009, 9: 53-10.1186/1472-6807-9-53.PubMedPubMed CentralView ArticleGoogle Scholar
- Wu D, Hu T, Zhang L, Chen J, Du J, Ding J, Jiang H, Shen X: Residues Asp164 and Glu165 at the substrate entryway function potently in substrate orientation of alanine racemase from E. coli: Enzymatic characterization with crystal structure analysis. Protein Sci. 2008, 17: 1066-1076. 10.1110/ps.083495908.PubMedPubMed CentralView ArticleGoogle Scholar
- Priyadarshi A, Lee EH, Sung MW, Nam KH, Lee WH, Kim EE, Hwang KY: Structural insights into the alanine racemase from Enterococcus faecalis. Biochim Biophys Acta. 2009, 1794: 1030-1040.PubMedView ArticleGoogle Scholar
- Ondrechen MJ, Briggs JM, McCammon JA: A model for enzyme-substrate interaction in alanine racemase. J Am Chem Soc. 2001, 123: 2830-2834. 10.1021/ja0029679.PubMedView ArticleGoogle Scholar
- Watanabe A, Yoshimura T, Mikami B, Esaki N: Tyrosine 265 of alanine racemase serves as a base abstracting alpha-hydrogen from L-alanine: the counterpart residue to lysine 39 specific to D-alanine. J Biochem. 1999, 126: 781-786.PubMedView ArticleGoogle Scholar
- Sun S, Toney MD: Evidence for a two-base mechanism involving tyrosine-265 from arginine-219 mutants of alanine racemase. Biochemistry. 1999, 38: 4058-4065. 10.1021/bi982924t.PubMedView ArticleGoogle Scholar
- Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al: Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998, 54: 905-921. 10.1107/S0907444998003254.PubMedView ArticleGoogle Scholar
- Schomaker V, Trueblood KN: On the rigid-body motion of molecules in crystals. Acta Crystallogr B. 1968, 24: 63-76. 10.1107/S0567740868001718.View ArticleGoogle Scholar
- Collaborative Computational Project Number 4: The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr D Biol Crystallogr. 1994, 50: 760-763. 10.1107/S0907444994003112.View ArticleGoogle Scholar
- Laskowski RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993, 26: 283-291. 10.1107/S0021889892009944.View ArticleGoogle Scholar
- Kleywegt GJ, Jones TA: Databases in protein crystallography. Acta Crystallogr D Biol Crystallogr. 1998, 54: 1119-1131. 10.1107/S0907444998007100.PubMedView ArticleGoogle Scholar
- Strych U, Benedik MJ: Mutant analysis shows that alanine racemases from Pseudomonas aeruginosa and Escherichia coli are dimeric. J Bacteriol. 2002, 184: 4321-4325. 10.1128/JB.184.15.4321-4325.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Yokoigawa K, Okubo Y, Soda K: Subunit interaction of monomeric alanine racemases from four Shigella species in catalytic reaction. FEMS Microbiol Lett. 2003, 221: 263-267. 10.1016/S0378-1097(03)00216-7.PubMedView ArticleGoogle Scholar
- Ju J, Xu S, Furukawa Y, Zhang Y, Misono H, Minamino T, Namba K, Zhao B, Ohnishi K: Correlation between catalytic activity and monomer-dimer equilibrium of bacterial alanine racemases. J Biochem. 2011, 149: 83-89. 10.1093/jb/mvq120.PubMedView ArticleGoogle Scholar
- Spies MA, Woodward JJ, Watnik MR, Toney MD: Alanine racemase free energy profiles from global analyses of progress curves. J Am Chem Soc. 2004, 126: 7464-7475. 10.1021/ja049579h.PubMedView ArticleGoogle Scholar
- Patrick WM, Weisner J, Blackburn JM: Site-directed mutagenesis of Tyr354 in Geobacillus stearothermophilus alanine racemase identifies a role in controlling substrate specificity and a possible role in the evolution of antibiotic resistance. Chembiochem. 2002, 3: 789-792. 10.1002/1439-7633(20020802)3:8<789::AID-CBIC789>3.0.CO;2-D.PubMedView ArticleGoogle Scholar
- Wang DF, Wiest O, Helquist P, Lan-Hargest HY, Wiech NL: On the function of the 14 Å long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem. 2004, 47: 3409-3417. 10.1021/jm0498497.PubMedView ArticleGoogle Scholar
- Boggetto N, Reboud-Ravaux M: Dimerization inhibitors of HIV-1 protease. Biol Chem. 2002, 383: 1321-1324. 10.1515/BC.2002.150.PubMedView ArticleGoogle Scholar
- Song M, Rajesh S, Hayashi Y, Kiso Y: Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg Med Chem Lett. 2001, 11: 2465-2468. 10.1016/S0960-894X(01)00468-1.PubMedView ArticleGoogle Scholar
- Strosberg AD: Breaking the spell: drug discovery based on modulating protein-protein interactions. Expert Rev Proteomics. 2004, 1: 141-143. 10.1586/147894126.96.36.199.PubMedView ArticleGoogle Scholar
- Scheer JM, Romanowski MJ, Wells JA: A common allosteric site and mechanism in caspases. Proc Natl Acad Sci USA. 2006, 103: 7595-7600. 10.1073/pnas.0602571103.PubMedPubMed CentralView ArticleGoogle Scholar
- Mustata G, Briggs JM: Cluster analysis of water molecules in alanine racemase and their putative structural role. Protein Eng Des Sel. 2004, 17: 223-234. 10.1093/protein/gzh033.PubMedView ArticleGoogle Scholar
- Teeter MM: Water structure of a hydrophobic protein at atomic resolution: Pentagon rings of water molecules in crystals of crambin. Proc Natl Acad Sci USA. 1984, 81: 6014-6018. 10.1073/pnas.81.19.6014.PubMedPubMed CentralView ArticleGoogle Scholar
- Weinstein L: Antimicrobial agents: drugs used in the chemotherapy of tuberculosis and leprosy. The pharmacological basis of therapeutics. Edited by: Goodman LS,Gilman A. 1975, New York: Macmillan Publishing Co. Inc, 1201-1223. 5Google Scholar
- Mustata GI, Briggs JM: A structure-based design approach for the identification of novel inhibitors: application to an alanine racemase. J Comput Aided Mol Des. 2002, 16: 935-953. 10.1023/A:1023875514454.PubMedView ArticleGoogle Scholar
- Smith MA, Mack V, Ebneth A, Moraes I, Felicetti B, Wood M, Schonfeld D, Mather O, Cesura A, Barker J: The structure of mammalian serine racemase: evidence for conformational changes upon inhibitor binding. J Biol Chem. 2010, 285: 12873-12881. 10.1074/jbc.M109.050062.PubMedPubMed CentralView ArticleGoogle Scholar
- Walsh C: Antibiotics: Actions, origins, resistance. 2003, Washington, DC: American Society for Microbiology PressView ArticleGoogle Scholar
- Otwinowski Z, Minor W: Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276: 307-326.View ArticleGoogle Scholar
- Matthews BW: Solvent content of protein crystals. J Mol Biol. 1968, 33: 491-497. 10.1016/0022-2836(68)90205-2.PubMedView ArticleGoogle Scholar
- Lamzin VS, Wilson KS: Automated refinement for protein crystallography. Methods Enzymol. 1997, 277: 269-305.PubMedView ArticleGoogle Scholar
- Painter J, Merritt EA: Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr. 2006, 62: 439-450. 10.1107/S0907444906005270.PubMedView ArticleGoogle Scholar
- Painter J, Merritt EA: TLSMD web server for the generation of multi-group TLS models. J Appl Crystallogr. 2006, 39: 109-111. 10.1107/S0021889805038987.View ArticleGoogle Scholar
- Krissinel E, Henrick K: Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr. 2004, 60: 2256-2268. 10.1107/S0907444904026460.PubMedView ArticleGoogle Scholar
- Krissinel E, Henrick K: Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007, 372: 774-797. 10.1016/j.jmb.2007.05.022.PubMedView ArticleGoogle Scholar
- Reynolds C, Damerell D, Jones S: ProtorP: a protein-protein interaction analysis server. Bioinformatics. 2009, 25: 413-414. 10.1093/bioinformatics/btn584.PubMedView ArticleGoogle Scholar
- DeLano WL: The PyMOL Molecular Graphics System. [http://www.pymol.org/]
- Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ: Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009, 25: 1189-1191. 10.1093/bioinformatics/btp033.PubMedPubMed CentralView ArticleGoogle Scholar
- Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA: Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA. 2001, 98: 10037-10041. 10.1073/pnas.181342398.PubMedPubMed CentralView ArticleGoogle Scholar
- Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA: PDB 2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004, 32: W665-667. 10.1093/nar/gkh381.PubMedPubMed CentralView ArticleGoogle Scholar
- Schuttelkopf AW, van Aalten DM: PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004, 60: 1355-1363. 10.1107/S0907444904011679.PubMedView ArticleGoogle Scholar
- Inagaki K, Tanizawa K, Badet B, Walsh CT, Tanaka H, Soda K: Thermostable alanine racemase from Bacillus stearothermophilus: molecular cloning of the gene, enzyme purification, and characterization. Biochemistry. 1986, 25: 3268-3274. 10.1021/bi00359a028.PubMedView ArticleGoogle Scholar
- Noda M, Matoba Y, Kumagai T, Sugiyama M: A novel assay method for an amino acid racemase reaction based on circular dichroism. Biochem J. 2005, 389: 491-496. 10.1042/BJ20041649.PubMedPubMed CentralView ArticleGoogle Scholar
- Badet B, Walsh C: Purification of an alanine racemase from Streptococcus faecalis and analysis of its inactivation by (1-aminoethyl)phosphonic acid enantiomers. Biochemistry. 1985, 24: 1333-1341. 10.1021/bi00327a010.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.